CDK4/6 inhibitors for metastatic breast cancer in routine clinical practice in Spain: survey of patterns of use and oncologists’ perceptions

Simple item page
dc.contributor.authorFernando Moreno
dc.contributor.authorVega Iranzo
dc.contributor.authorI. Álvarez
dc.contributor.authorAntonio Antón
dc.contributor.authorJosé Ignacio Chacón
dc.contributor.authorJoaquín Gavilá
dc.contributor.authorMichael S. Martin
dc.contributor.authorPedro Sánchez‐Rovira
dc.contributor.authorPaula Gratal
dc.contributor.authorM J Fernández González
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T15:39:16Z
dc.date.available2026-03-22T15:39:16Z
dc.date.issued2025
dc.descriptionCitaciones: 1
dc.identifier.doi10.1007/s12094-025-03896-z
dc.identifier.urihttps://doi.org/10.1007/s12094-025-03896-z
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/53629
dc.language.isoen
dc.publisherSpringer Science+Business Media
dc.relation.ispartofClinical & Translational Oncology
dc.sourceHospital Clínico San Carlos
dc.subjectMedicine
dc.subjectFulvestrant
dc.subjectBreast cancer
dc.subjectOncology
dc.subjectEndocrine system
dc.subjectInternal medicine
dc.subjectDisease
dc.subjectClinical Practice
dc.subjectAromatase
dc.subjectCancer
dc.titleCDK4/6 inhibitors for metastatic breast cancer in routine clinical practice in Spain: survey of patterns of use and oncologists’ perceptions
dc.typearticle

Files

Collections

Artículo Científico Publicado